Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort

• Published in: Cancer epidemiology, biomarkers & prevention Vol. 33; no. 11; pp. 1500 - 1511
• Main Authors: Liss, Michael A., Zeltser, Nicole, Zheng, Yingye, Lopez, Camden, Liu, Menghan, Patel, Yash, Yamaguchi, Takafumi N., Eng, Stefan E., Tian, Mao, Semmes, Oliver J., Lin, Daniel W., Brooks, James D., Wei, John T., Klein, Eric A., Tewari, Ashutosh K., Mosquera, Juan Miguel, Khani, Francesca, Robinson, Brian D., Aasad, Muhammad, Troyer, Dean A., Kagan, Jacob, Sanda, Martin G., Thompson, Ian M., Boutros, Paul C., Leach, Robin J.
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 01.11.2024
• Subjects: Aged; Biomarkers; Dna Damage And Repair; Genitourinary Cancers; Germ-Line Mutation; Humans; Male; Middle Aged; Neoplasm Grading; Prospective Studies; Prostatectomy - methods; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Prostatic Neoplasms - surgery; Risk Factors
• ISSN: 1055-9965; 1538-7755; 1538-7755
• DOI: 10.1158/1055-9965.EPI-24-0326

Localized prostate tumors show significant spatial heterogeneity, with regions of high-grade disease adjacent to lower grade disease. Consequently, prostate cancer biopsies are prone to sampling bias, potentially leading to underestimation of tumor grade. To study the clinical, epidemiologic, and molecular hallmarks of this phenomenon, we conducted a prospective study of grade upgrading: differences in detected prostate cancer grade between biopsy and surgery. We established a prospective, multi-institutional cohort of men with grade group 1 (GG1) prostate cancer on biopsy who underwent radical prostatectomy. Upgrading was defined as detection of GG2+ in the resected tumor. Germline DNA from 192 subjects was subjected to whole-genome sequencing to quantify ancestry, pathogenic variants in DNA damage response genes, and polygenic risk. Of 285 men, 67% upgraded at surgery. PSA density and percent of cancer in pre-prostatectomy positive biopsy cores were significantly associated with upgrading. No assessed genetic risk factor was predictive of upgrading, including polygenic risk scores for prostate cancer diagnosis. In a cohort of patients with low-grade prostate cancer, a majority upgraded at radical prostatectomy. PSA density and percent of cancer in pre-prostatectomy positive biopsy cores portended the presence of higher-grade disease, while germline genetics was not informative in this setting. Patients with low-risk prostate cancer, but elevated PSA density or percent cancer in positive biopsy cores, may benefit from repeat biopsy, additional imaging or other approaches to complement active surveillance. Further risk stratification of patients with low-risk prostate cancer may provide useful context for active surveillance decision-making.